{"license":"https://creativecommons.org/licenses/by/4.0/","dataset":"event-entities","count":6,"summary":{"policyEntityCount":21,"relationshipCount":31,"officialEventCount":14,"linkedEventCount":12,"unlinkedEventCount":2,"marketCount":7,"sourceCount":11,"agencyCount":4,"profileCrosswalkCount":6,"firstYear":2019,"latestYear":2026,"spanLabel":"2019-2026"},"guardrail":"A relationship means an official source names the organization in connection with the dated record. It does not by itself establish liability, market power, ownership, control, or that the organization participates in every market linked to that record.","crosswalkGuardrail":"Optional participant and operator crosswalks are observatory navigation aids based on matched public labels. They are not legal-entity, affiliate, beneficial-owner, or corporate-control determinations.","eventFilters":{"event":"evt-pbm-insulin-complaint-2024","eventMatched":true,"events":null,"eventsMatched":null,"matchedEventCount":null,"matchedEventIds":null,"unmatchedEvents":null,"stage":null,"stageMatched":null,"type":null,"typeMatched":null,"agency":null,"proceeding":null,"proceedingMatched":null,"proceedingId":null,"proceedingSlug":null},"rows":[{"id":"peel-ascent-complaint","eventId":"evt-pbm-insulin-complaint-2024","eventDate":"2024-09-20","eventTitle":"FTC files administrative complaint against the three largest PBMs","eventStage":"litigation","eventType":"complaint","agency":"Federal Trade Commission","docketNumber":"Docket No. 9437","entityId":"pent-ascent-health","entitySlug":"ascent-health-services-llc","entityName":"Ascent Health Services, LLC","role":"respondent","roleLabel":"Respondent","evidenceSummary":"The FTC administrative complaint names affiliated GPO Ascent Health Services as a respondent.","markets":[{"id":"mkt-pbm","slug":"us-pharmacy-benefit-management","name":"U.S. pharmacy benefit management"}],"sourceId":"ftc-pbm-insulin-complaint-2024","sourceTitle":"FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices","sourcePublisher":"Federal Trade Commission","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices","sourceAccessDate":"2026-07-17","profileHref":null,"profileKind":null,"policyEntityProfileHref":"/enforcement/entities/ascent-health-services-llc","recordProfileHref":"/enforcement/records/pbm-insulin-complaint-2024","enforcementHref":"/enforcement?policyEntity=ascent-health-services-llc&enforcementEvent=evt-pbm-insulin-complaint-2024#enforcement-relationship-atlas","guardrail":"A relationship means an official source names the organization in connection with the dated record. It does not by itself establish liability, market power, ownership, control, or that the organization participates in every market linked to that record.","crosswalkGuardrail":"Optional participant and operator crosswalks are observatory navigation aids based on matched public labels. They are not legal-entity, affiliate, beneficial-owner, or corporate-control determinations.","sourceProfileHref":"/sources/ftc-pbm-insulin-complaint-2024"},{"id":"peel-caremark-complaint","eventId":"evt-pbm-insulin-complaint-2024","eventDate":"2024-09-20","eventTitle":"FTC files administrative complaint against the three largest PBMs","eventStage":"litigation","eventType":"complaint","agency":"Federal Trade Commission","docketNumber":"Docket No. 9437","entityId":"pent-caremark-rx","entitySlug":"caremark-rx-llc","entityName":"Caremark Rx, LLC","role":"respondent","roleLabel":"Respondent","evidenceSummary":"The FTC administrative complaint names Caremark Rx as a respondent.","markets":[{"id":"mkt-pbm","slug":"us-pharmacy-benefit-management","name":"U.S. pharmacy benefit management"}],"sourceId":"ftc-pbm-insulin-complaint-2024","sourceTitle":"FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices","sourcePublisher":"Federal Trade Commission","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices","sourceAccessDate":"2026-07-17","profileHref":null,"profileKind":null,"policyEntityProfileHref":"/enforcement/entities/caremark-rx-llc","recordProfileHref":"/enforcement/records/pbm-insulin-complaint-2024","enforcementHref":"/enforcement?policyEntity=caremark-rx-llc&enforcementEvent=evt-pbm-insulin-complaint-2024#enforcement-relationship-atlas","guardrail":"A relationship means an official source names the organization in connection with the dated record. It does not by itself establish liability, market power, ownership, control, or that the organization participates in every market linked to that record.","crosswalkGuardrail":"Optional participant and operator crosswalks are observatory navigation aids based on matched public labels. They are not legal-entity, affiliate, beneficial-owner, or corporate-control determinations.","sourceProfileHref":"/sources/ftc-pbm-insulin-complaint-2024"},{"id":"peel-emisar-complaint","eventId":"evt-pbm-insulin-complaint-2024","eventDate":"2024-09-20","eventTitle":"FTC files administrative complaint against the three largest PBMs","eventStage":"litigation","eventType":"complaint","agency":"Federal Trade Commission","docketNumber":"Docket No. 9437","entityId":"pent-emisar-pharma","entitySlug":"emisar-pharma-services-llc","entityName":"Emisar Pharma Services LLC","role":"respondent","roleLabel":"Respondent","evidenceSummary":"The FTC administrative complaint names affiliated GPO Emisar Pharma Services as a respondent.","markets":[{"id":"mkt-pbm","slug":"us-pharmacy-benefit-management","name":"U.S. pharmacy benefit management"}],"sourceId":"ftc-pbm-insulin-complaint-2024","sourceTitle":"FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices","sourcePublisher":"Federal Trade Commission","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices","sourceAccessDate":"2026-07-17","profileHref":null,"profileKind":null,"policyEntityProfileHref":"/enforcement/entities/emisar-pharma-services-llc","recordProfileHref":"/enforcement/records/pbm-insulin-complaint-2024","enforcementHref":"/enforcement?policyEntity=emisar-pharma-services-llc&enforcementEvent=evt-pbm-insulin-complaint-2024#enforcement-relationship-atlas","guardrail":"A relationship means an official source names the organization in connection with the dated record. It does not by itself establish liability, market power, ownership, control, or that the organization participates in every market linked to that record.","crosswalkGuardrail":"Optional participant and operator crosswalks are observatory navigation aids based on matched public labels. They are not legal-entity, affiliate, beneficial-owner, or corporate-control determinations.","sourceProfileHref":"/sources/ftc-pbm-insulin-complaint-2024"},{"id":"peel-express-scripts-complaint","eventId":"evt-pbm-insulin-complaint-2024","eventDate":"2024-09-20","eventTitle":"FTC files administrative complaint against the three largest PBMs","eventStage":"litigation","eventType":"complaint","agency":"Federal Trade Commission","docketNumber":"Docket No. 9437","entityId":"pent-express-scripts","entitySlug":"express-scripts-inc","entityName":"Express Scripts, Inc.","role":"respondent","roleLabel":"Respondent","evidenceSummary":"The FTC administrative complaint names Express Scripts as a respondent.","markets":[{"id":"mkt-pbm","slug":"us-pharmacy-benefit-management","name":"U.S. pharmacy benefit management"}],"sourceId":"ftc-pbm-insulin-complaint-2024","sourceTitle":"FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices","sourcePublisher":"Federal Trade Commission","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices","sourceAccessDate":"2026-07-17","profileHref":null,"profileKind":null,"policyEntityProfileHref":"/enforcement/entities/express-scripts-inc","recordProfileHref":"/enforcement/records/pbm-insulin-complaint-2024","enforcementHref":"/enforcement?policyEntity=express-scripts-inc&enforcementEvent=evt-pbm-insulin-complaint-2024#enforcement-relationship-atlas","guardrail":"A relationship means an official source names the organization in connection with the dated record. It does not by itself establish liability, market power, ownership, control, or that the organization participates in every market linked to that record.","crosswalkGuardrail":"Optional participant and operator crosswalks are observatory navigation aids based on matched public labels. They are not legal-entity, affiliate, beneficial-owner, or corporate-control determinations.","sourceProfileHref":"/sources/ftc-pbm-insulin-complaint-2024"},{"id":"peel-optumrx-complaint","eventId":"evt-pbm-insulin-complaint-2024","eventDate":"2024-09-20","eventTitle":"FTC files administrative complaint against the three largest PBMs","eventStage":"litigation","eventType":"complaint","agency":"Federal Trade Commission","docketNumber":"Docket No. 9437","entityId":"pent-optumrx","entitySlug":"optumrx-inc","entityName":"OptumRx, Inc.","role":"respondent","roleLabel":"Respondent","evidenceSummary":"The FTC administrative complaint names OptumRx as a respondent.","markets":[{"id":"mkt-pbm","slug":"us-pharmacy-benefit-management","name":"U.S. pharmacy benefit management"}],"sourceId":"ftc-pbm-insulin-complaint-2024","sourceTitle":"FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices","sourcePublisher":"Federal Trade Commission","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices","sourceAccessDate":"2026-07-17","profileHref":null,"profileKind":null,"policyEntityProfileHref":"/enforcement/entities/optumrx-inc","recordProfileHref":"/enforcement/records/pbm-insulin-complaint-2024","enforcementHref":"/enforcement?policyEntity=optumrx-inc&enforcementEvent=evt-pbm-insulin-complaint-2024#enforcement-relationship-atlas","guardrail":"A relationship means an official source names the organization in connection with the dated record. It does not by itself establish liability, market power, ownership, control, or that the organization participates in every market linked to that record.","crosswalkGuardrail":"Optional participant and operator crosswalks are observatory navigation aids based on matched public labels. They are not legal-entity, affiliate, beneficial-owner, or corporate-control determinations.","sourceProfileHref":"/sources/ftc-pbm-insulin-complaint-2024"},{"id":"peel-zinc-complaint","eventId":"evt-pbm-insulin-complaint-2024","eventDate":"2024-09-20","eventTitle":"FTC files administrative complaint against the three largest PBMs","eventStage":"litigation","eventType":"complaint","agency":"Federal Trade Commission","docketNumber":"Docket No. 9437","entityId":"pent-zinc-health","entitySlug":"zinc-health-services-llc","entityName":"Zinc Health Services, LLC","role":"respondent","roleLabel":"Respondent","evidenceSummary":"The FTC administrative complaint names affiliated GPO Zinc Health Services as a respondent.","markets":[{"id":"mkt-pbm","slug":"us-pharmacy-benefit-management","name":"U.S. pharmacy benefit management"}],"sourceId":"ftc-pbm-insulin-complaint-2024","sourceTitle":"FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices","sourcePublisher":"Federal Trade Commission","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices","sourceAccessDate":"2026-07-17","profileHref":null,"profileKind":null,"policyEntityProfileHref":"/enforcement/entities/zinc-health-services-llc","recordProfileHref":"/enforcement/records/pbm-insulin-complaint-2024","enforcementHref":"/enforcement?policyEntity=zinc-health-services-llc&enforcementEvent=evt-pbm-insulin-complaint-2024#enforcement-relationship-atlas","guardrail":"A relationship means an official source names the organization in connection with the dated record. It does not by itself establish liability, market power, ownership, control, or that the organization participates in every market linked to that record.","crosswalkGuardrail":"Optional participant and operator crosswalks are observatory navigation aids based on matched public labels. They are not legal-entity, affiliate, beneficial-owner, or corporate-control determinations.","sourceProfileHref":"/sources/ftc-pbm-insulin-complaint-2024"}]}